WELLBUTRIN® (bupropion hydrochloride) is an aminoketone antidepressant indicated for the treatment of major depressive disorder (MDD). Unlike other known antidepressant agents, it is chemically unrelated to tricyclics, tetracyclics, selective serotonin reuptake inhibitors, or other such agents. Bupropion's structure closely resembles that of diethylpropion, and it is related to phenylethylamines. It is presumed that the exact mechanism of bupropion's antidepressant action is related to noradrenergic and/or dopaminergic mechanisms, although it is not fully understood. Bupropion hydrochloride powder is white, crystalline, and highly soluble in water. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. GSK Plc first approved WELLBUTRIN in the United States in 1985. Click on the image below to begin the exploration journey of Wellbutrin through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!